North Central London
Joint Formulary
 
back
8 Malignant disease and immunosuppression

The formulary for systemic anti-cancer treatments should be viewed alongside the 'National Cancer Drugs Fund list'

https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/

08-01-05 Bevacizumab

Bevacizumab
Restricted

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
    • Discuss with cancer pharmacy team before prescribing
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA118 (not recommended): Bevacizumab for the treatment of metastatic colorectal cancer
Link  NICE TA148 (not recommended): Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal)
Link  NICE TA178 (not recommended): Bevacizumab (1st line), sorafenib, sunitinib (2nd line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA212 (not recommended): Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Link  NICE TA214 (not recommended): Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
Link  NICE TA242 (not recommended): Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy
Link  NICE TA263 (not recommended): Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
Link  NICE TA284 (not recommended): Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Link  NICE TA285 (not recommended): Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
Link  NICE TA353 (not recommended): Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)
Link  NICE TA436 (not recommended): Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)
Link  NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
 

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF  HCD  CDF